Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
213.5 USD | -1.21% | +5.70% | -17.49% |
Apr. 30 | Wall Street: buoyed by Tesla, confident ahead of FOMC meeting | CF |
Apr. 29 | Wall Street: buoyed by Tesla, confident ahead of FOMC meeting | CF |
Chart calendar Biogen Inc.
Upcoming events on Biogen Inc.
Past events on Biogen Inc.
2024-04-24 08:30 am | Q1 2024 Earnings Call |
2024-04-23 | Q1 2024 Earnings Release Pre-market |
2024-03-19 10:00 am | Stifel Virtual CNS Day |
2024-03-09 04:10 pm | Alzheimer and Parkinson Diseases International Conference |
2024-03-09 04:10 am | Alzheimer and Parkinson Diseases International Conference - The extension of efficacy results from C |
2024-03-08 01:55 pm | Alzheimer and Parkinson Diseases International Conference - Oral Presentation |
2024-03-08 04:55 am | Alzheimer and Parkinson Diseases International Conference - Oral Presentation |
2024-03-08 04:55 am | Alzheimer and Parkinson Diseases International Conference - Occupancy of BIIB113 |
2024-03-08 01:55 am | Alzheimer and Parkinson Diseases International Conference - Distribution of Alpha-Synuclein co-patho |
2024-03-07 08:50 am | Alzheimer and Parkinson Diseases International Conference - Oral Presentation |
2024-03-07 08:50 am | Alzheimer and Parkinson Diseases International Conference - Eisai |
2024-03-06 04:00 am | Alzheimer and Parkinson Diseases International Conference - P#0250 |
2024-03-04 | Alzheimer and Parkinson Diseases International Conference - A Neuro-Dynamic Quantitative Systems Pha |
2024-03-04 11:10 am | TD Cowen Health Care Conference |
2024-02-13 08:00 am | Q4 2023 Earnings Call |
2024-02-13 06:59 am | Q4 2023 Earnings Release |
2024-01-08 02:15 pm | JPMorgan Healthcare Conference |
2023-11-28 09:10 am | Evercore ISI HealthCONx Conference |
2023-11-08 08:00 am | Q3 2023 Earnings Call |
2023-11-08 06:59 am | Q3 2023 Earnings Release |
Past dividends on Biogen Inc.
2017-02-01 | 0 |
Annual results
Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 14 378 14 239 0.98% | 13 445 13 368 0.57% | 10 982 10 870 1.03% | 10 173 10 069 1.04% | 9 836 9 931 -0.96% | 9 527 |
EBITDA Million USD | Released Forecast Spread | 8 070 8 396 -3.88% | 7 504 7 558 -0.72% | 4 144 4 352 -4.78% | 3 618 3 835 -5.67% | 3 040 2 979 2.05% | 3 409 |
EBIT Million USD | Released Forecast Spread | 7 390 7 579 -2.5% | 6 837 6 993 -2.23% | 3 656 3 692 -0.97% | 3 099 3 206 -3.31% | 2 545 2 574 -1.13% | 2 872 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 7 126 6 968 2.26% | 5 048 5 524 -8.62% | 1 745 1 883 -7.31% | 3 592 3 549 1.21% | 1 297 1 522 -14.79% | 2 257 |
Net income Million USD | Released Forecast Spread | 5 889 5 757 2.29% | 4 001 4 281 -6.55% | 1 556 1 618 -3.81% | 3 047 2 877 5.9% | 1 161 1 318 -11.92% | 1 896 |
EPS USD | Released Forecast Spread | 31,4 30,8 2.14% | 24,8 26,6 -6.86% | 10,4 10,8 -3.49% | 20,9 20,2 3.13% | 7,97 10,5 -23.78% | 13,1 |
Announcement Date | 30/01/20 | 03/02/21 | 03/02/22 | 15/02/23 | 13/02/24 | - |
Quarterly results
Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 2 532 2 504 1.09% | 2 589 2 477 4.53% | 2 509 2 468 1.65% | 2 544 2 442 4.19% | 2 463 2 343 5.12% | 2 456 2 363 3.95% | 2 530 2 399 5.48% | 2 386 2 463 -3.13% | 2 291 2 315 -1.08% | 2 383 | 2 408 | 2 447 | 2 365 | 2 413 |
EBITDA Million USD | Released Forecast Spread | 844 904 -6.6% | 1 112 874 27.17% | 991 875 13.26% | 793 799 -0.83% | 675 624 8.06% | 798 808 -1.25% | 853 880 -3.06% | 698 894 -21.97% | 796 804 -1.1% | 956 | 982 | 1 024 | ||
EBIT Million USD | Released Forecast Spread | 709 794 -10.81% | 977 778 25.53% | 870 779 11.73% | 673 664 1.39% | 468 621 -24.66% | 674 672 0.29% | 728 700 4.07% | 557 603 -7.58% | 648 647 0.21% | 719 | 735 | 726 | 718 | 752 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 347 703 -50.58% | 1 270 850 49.41% | 1 371 649 111.12% | 604 673 -10.3% | 438 585 -25.08% | 708 812 -12.82% | -141 562 -125.13% | 292 472 -38.19% | 465 457 1.74% | 627 | 545 | 550 | 512 | 527 |
Net income Million USD | Released Forecast Spread | 304 550 -44.77% | 1 058 732 44.49% | 1 135 503 125.52% | 550 461 19.37% | 388 366 5.86% | 592 542 9.25% | -68,1 491 -113.88% | 250 383 -34.8% | 393 360 9.36% | 526 | 481 | 490 | 458 | 488 |
EPS USD | Released Forecast Spread | 2,06 3,74 -44.94% | 7,24 5,55 30.43% | 7,84 3,68 112.82% | 3,79 3,12 21.33% | 2,67 2,71 -1.64% | 4,07 4,90 -16.86% | -0,47 3,41 -113.77% | 1,71 3,48 -50.85% | 2,70 2,64 2.32% | 3,60 | 3,18 | 3,36 | 3,29 | 3,41 |
Announcement Date | 03/05/22 | 20/07/22 | 25/10/22 | 15/02/23 | 25/04/23 | 25/07/23 | 08/11/23 | 13/02/24 | 24/04/24 | - | - | - | - | - |
2024-05-06 07:00 am | AXSOME THERAPEUTICS, INC.: Q1 2024 Earnings Release |
2024-05-06 | BIOTEST AG: Q1 2024 Earnings Release |
2024-05-06 | AVIDITY BIOSCIENCES, INC.: Q1 2024 Earnings Release (Projected) |
2024-05-06 | REVANCE THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
2024-05-06 | APELLIS PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
2024-05-07 02:00 am | BIOGAIA AB: Q1 2024 Earnings Release |
2024-05-07 | ADMA BIOLOGICS, INC.: Q1 2024 Earnings Release (Projected) |
2024-05-07 | INTRA-CELLULAR THERAPIES, INC.: Q1 2024 Earnings Release (Projected) |
2024-05-07 | CATALYST PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
2024-05-07 | ZAI LAB LIMITED: Q1 2024 Earnings Release |
Past sector events for Biogen Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- BIIB Stock
- Calendar Biogen Inc.